Pylera

Product NDC: 58914-601
11-digit product format: 589140601
Labeler code: 58914
Product ID: 58914-601_8ba040ec-d48a-45e8-a2e2-3e3b9ca7c41d
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride
Dosage form: CAPSULE
Route: ORAL
Labeler: Allergan, Inc.
Application: NDA050786
Marketing category: NDA
Marketing start: 2013-08-01
Marketing end: 0000-00-00
Substance: BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
Active strength: 140 mg/1; mg/1; mg/1
Pharmacologic classes: Bismuth [CS], Bismuth [EPC], Nitroimidazole Antimicrobial [EPC], Nitroimidazoles [CS], Tetracycline-class Antimicrobial [EPC], Tetracyclines [CS]
NDC exclude flag: No
Listing certified through: 2023-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 3 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	58914-601		D	Discontinued by firm	2026-08-10
excluded package	package	58914-601	58914-601-20	D	Discontinued by firm	2026-08-10
excluded package	package	58914-601	58914-601-21	D	Discontinued by firm	2026-08-10

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 30 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	58914-601-20	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	58914-601-21	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	58914-601-20	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	58914-601-21	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	58914-601-20	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	58914-601-21	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	58914-601-20	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	58914-601-21	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	58914-601-20	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	58914-601-21	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	58914-601-20	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	58914-601-21	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	58914-601-20	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	58914-601-21	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	58914-601-20	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	58914-601-21	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	58914-601-20	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	58914-601-21	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	58914-601-20	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	58914-601-21	`ad56d346431e…`	`cc804d4bbf1e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N050786-001	PYLERA	BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-product	TE code
N050786-001	AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 41 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`ea99ee380514…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`a72a2bbeb626…`
2023-10-25 00:34 UTC · 2 captures of this ZIP	2023-10	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`9b2671bbb829…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`a67488948f0b…`
2023-06-13 01:57 UTC · 3 captures of this ZIP	2023-06	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`3f0d92c62455…`
2023-05-13 08:27 UTC	2023-05	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL	AB	RLD, RS	2006-09-28	`053a50430f4f…`
2023-01-26 05:58 UTC	2023-01	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N050786-001	PYLERA	140MG;125MG;125MG	CAPSULE / ORAL		RLD, RS	2006-09-28	`cb3db0bc1861…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N050786-001	AB	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N050786-001	AB	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N050786-001	AB	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N050786-001	AB	1	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N050786-001	AB	1	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N050786-001	AB	1	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N050786-001	AB	1	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N050786-001	AB	1	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N050786-001	AB	1	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N050786-001	AB	1	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N050786-001	AB	1	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N050786-001	AB	1	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N050786-001	AB	1	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N050786-001	AB	1	`8072bd15b7f6…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N050786-001	AB	1	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	N050786-001	AB	1	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	N050786-001	AB	1	`ea1830bbd6c7…`
2023-11-28 05:40 UTC · 2 captures of this ZIP	2023-11	N050786-001	AB	1	`a72a2bbeb626…`
2023-10-25 00:34 UTC · 2 captures of this ZIP	2023-10	N050786-001	AB	1	`9b2671bbb829…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	N050786-001	AB	1	`a67488948f0b…`
2023-06-13 01:57 UTC · 3 captures of this ZIP	2023-06	N050786-001	AB	1	`3f0d92c62455…`
2023-05-13 08:27 UTC	2023-05	N050786-001	AB	1	`053a50430f4f…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N050786-001	AB	1	`a50c72e98297…`

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
58914-601-20	EA - Each	58914-601	5ca2fda0-d4dd-4e67-bb17-633e498d41f7	1	2013-07-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
Bismuth subcitrate potassium	ACTIVE INGREDIENT	R3O80H60KX	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Metronidazole	ACTIVE INGREDIENT	140QMO216E	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Tetracycline hydrochloride	ACTIVE INGREDIENT	P6R62377KV	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
BISMUTH CATION	ACTIVE MOIETY	ZS9CD1I8YE	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Metronidazole	ACTIVE MOIETY	140QMO216E	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Tetracycline	ACTIVE MOIETY	F8VB5M810T	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Gelatin	INACTIVE INGREDIENT	2G86QN327L	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Lactose monohydrate	INACTIVE INGREDIENT	EWQ57Q8I5X	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Magnesium stearate	INACTIVE INGREDIENT	70097M6I30	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Talc	INACTIVE INGREDIENT	7SEV7J4R1U	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10
Titanium dioxide	INACTIVE INGREDIENT	15FIX9V2JP	PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE) CAPSULE [APTALIS PHARMA US, INC.]	10

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
PYLERA	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE	H2-Pharma, LLC	5cdacbf5-67be-42eb-bd54-8acc32ea1abc	2026-06-29	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 050786 application number: NDA050786
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE	H2-Pharma, LLC	c29bfde9-5eb4-422a-bd30-4bce45e73dc0	2026-04-13	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 050786 application number: NDA050786
PYLERA	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE	H2-Pharma, LLC	c50626a2-5969-490b-a88a-a4ee45e79615	2026-01-16	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 050786 application number: NDA050786

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
R3O80H60KX	BISMUTH SUBCITRATE POTASSIUM		BISMUTH SUBCITRATE POTASSIUM
140QMO216E	METRONIDAZOLE	443-48-1	METRONIDAZOLE
P6R62377KV	TETRACYCLINE HYDROCHLORIDE	64-75-5	TETRACYCLINE HYDROCHLORIDE

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
58914-601-20	58914060120	1 BLISTER PACK in 1 BOX (58914-601-20) > 120 CAPSULE in 1 BLISTER PACK	1 blister pack	2013-08-01	0000-00-00	No	No	Current
58914-601-21	58914060121	1 BOTTLE in 1 BOX (58914-601-21) > 120 CAPSULE in 1 BOTTLE	1 bottle	2013-08-01	0000-00-00	No	No	Current